A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Launched by IPSEN · Nov 3, 2010
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Out-patients 18 years of age and older, who have agreed to participate in the study
- • Diagnosed with a Neuroendocrine tumour (NET) and receiving treatment with Somatuline Autogel
- Exclusion Criteria:
- • Subjects for whom there are reasons that may hinder the conduct of the study (patients who have difficulty expressing themselves or who are unable to complete the questionnaires, or with insufficient data in the their files will not be enrolled in the study).
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Warszawa, , Poland
London, , United Kingdom
Lyon, , France
Villejuif, , France
Liverpool, , United Kingdom
Budapest, , Hungary
Clichy, , France
Madrid, , Spain
Bordeaux, , France
Marseille, , France
Nice, , France
Sevilla, , Spain
Cardiff, , United Kingdom
Toulouse, , France
Bobigny, , France
Zaragoza, , Spain
Angers, , France
Newcastle Upon Tyne, , United Kingdom
Reims, , France
Barcelona, , Spain
San Giovanni Rotondo, , Italy
Barakaldo, , Spain
Praha, , Czechia
Coventry, , United Kingdom
Brno, , Czechia
Hradec Kralove, , Czechia
Pardubice, , Czechia
Plzen, , Czechia
Praha, , Czechia
Chambray Les Tours, , France
Grenoble, , France
Pessac, , France
Saint Priest, , France
Pécs, , Hungary
Jerusalem, , Israel
Albano Laziale, , Italy
Alzano Lombardo, , Italy
Castelfranco Veneto, , Italy
Chieti, , Italy
Cremona, , Italy
Modena, , Italy
Roma, , Italy
Roma, , Italy
Viagrande, , Italy
Bydgoszcz, , Poland
Katowice, , Poland
Krakow, , Poland
Lodz, , Poland
Olsztyn, , Poland
Poznan, , Poland
Szczecin, , Poland
Warszawa, , Poland
Warszawa, , Poland
Cordoba, , Spain
La Coruña, , Spain
Pontevedra, , Spain
Manchester, , United Kingdom
Patients applied
Trial Officials
Ipsen Study Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials